Survodutide

Survodutide (Inj)

Survodutide (BI 456906) is an investigational incretin-based peptide engineered as a dual agonist of the glucagon receptor (GCGR) and GLP‑1 receptor (GLP‑1R). It is studied for obesity and metabolic disease due to appetite suppression and energy expenditure effects. It remains under clinical development and is not a general-use peptide.

Dosing Protocols

Reconstitute: Add 2.0 mL bacteriostatic water → 5 mg/mL (5000 mcg/mL) concentration.
Typical weekly range: 0.6–6.0 mg once weekly (gradual titration over 10–12 weeks).
Easy measuring: At 5 mg/mL, 1 unit = 0.01 mL = 50 mcg on a U-100 insulin syringe.
Storage: Lyophilized: freeze at ≤−20 °C; reconstituted: refrigerate at 2–8 °C, protect from light.

Schedule: Weekly subcutaneous injections for 12–16 weeks (or longer as studied in phase 3 trials).
Cycle Length: 12–16 weeks minimum; phase 3 trials extend to 48–72 weeks.
Goal: Support metabolic improvement and weight management through dual GLP-1/glucagon receptor activation.

Frequency: Inject once weekly subcutaneously.

Phase	Dose	Syringe (U-100)
Weeks 1–2	0.6 mg	12 units (0.12 mL)
Weeks 3–4	1.2 mg	24 units (0.24 mL)
Weeks 5–6	1.8 mg	36 units (0.36 mL)
Weeks 7–8	2.4 mg	48 units (0.48 mL)
Weeks 9–10	3.6 mg	72 units (0.72 mL)
Weeks 11–12	4.8 mg	96 units (0.96 mL)
Week 13+	6.0 mg	120 units (1.20 mL)*

Benefits

• Clinically studied for weight loss in obesity
• May improve glycemic control and insulin sensitivity
• Appetite reduction and increased satiety (GLP‑1R-mediated)
• Potential increase in energy expenditure and lipid oxidation (GCGR-mediated)
• May reduce liver fat and improve metabolic markers in NAFLD/NASH research
• Improvements in cardiometabolic risk markers (blood pressure, lipids) observed with incretin therapies (class effect)

Mechanism of Action

Dual agonism: GLP‑1R activation enhances glucose-dependent insulin secretion, slows gastric emptying, and reduces appetite via central satiety pathways. GCGR activation increases hepatic glucose output acutely but also promotes energy expenditure, lipolysis, and potentially brown adipose activation. Balanced co-agonism aims to preserve weight-loss benefits while mitigating hyperglycemia risk.

Side Effects

• Nausea
• Vomiting
• Diarrhea or constipation
• Abdominal pain
• Decreased appetite
• Injection site reactions
• Potential gallbladder events (class effect)
• Potential pancreatitis risk (rare; class precaution)
• Hypoglycemia risk when combined with insulin/sulfonylureas

Side Effect Management

• Slow titration; start with lowest studied dose and escalate per protocol
• Smaller meals, avoid high-fat meals during escalation
• Hydration/electrolytes for GI symptoms
• Monitor for severe abdominal pain (pancreatitis/gallbladder warning)
• Adjust concomitant hypoglycemic meds in study settings

Contraindications

• Personal/family history of medullary thyroid carcinoma or MEN2 (GLP-1 class warning)
• History of pancreatitis (precaution)
• Severe gastroparesis
• Pregnancy/breastfeeding
• Use with insulin/sulfonylureas requires strict monitoring

Research Citations

PubMed/DOI-linked citations for verification. Many studies are preclinical (animal/in-vitro) or early clinical.

1. Ahrén B. GLP-1 receptor agonists for type 2 diabetes: efficacy and safety (review). DOI Link
2. Müller TD et al. Glucagon-like peptide 1 (GLP-1) and glucagon co-agonists for obesity. (review). DOI Link
3. Dual GLP-1/glucagon receptor agonism as a therapeutic strategy for obesity and NASH (review). DOI Link
4. Clinical development of survodutide (BI 456906) in obesity (trial report). DOI Link

---